Gabarap Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GABARAP (GABA Type A Receptor-Associated Protein) is a ubiquitin-like protein belonging to the ATG8 family. It plays essential roles in autophagy, intracellular trafficking, and GABA receptor clustering in neurons[1]. As a member of the ATG8 family, GABARAP is involved in autophagosome formation and function, making it critical for cellular protein quality control in the nervous system.
The GABARAP family includes four members in mammals: GABARAP, GABARAPL1 (GATE-16), GABARAPL2 (GABARAP-like 2), and MAP1LC3A/B/C (LC3). Each family member has distinct expression patterns and functions, with GABARAP showing highest expression in the brain[2].
| GABARAP | |
|---|---|
| Gene | [GABARAP](/genes/gabarap) |
| UniProt ID | [O95166](https://www.uniprot.org/uniprot/O95166) |
| PDB Structure | 1GNU, 2K2D, 5YHF |
| Molecular Weight | ~14 kDa |
| Subcellular Localization | Cytosolic, membrane-associated |
| Protein Family | ATG8/MAP1LC3 family |
| Aliases | GABAARAP, FLC3A, APG8L |
GABARAP is a ubiquitin-like protein with several distinct structural features[3]:
GABARAP shares structural homology with LC3 but has distinct properties:
| Feature | GABARAP | LC3 |
|---|---|---|
| Size | 117 aa | 146 aa |
| Hydrophobic pocket | More hydrophobic | Less hydrophobic |
| Lipidation efficiency | Higher | Moderate |
| Receptor binding | Broader specificity | Narrower |
GABARAP undergoes post-translational lipidation (phosphatidylethanolamine conjugation) essential for its function in autophagosome formation.
GABARAP function is regulated by various post-translational modifications:
| Modification | Site | Effect |
|---|---|---|
| Lipidation | Gly117 | Membrane association |
| Phosphorylation | Ser3, Ser47 | Interaction regulation |
| Acetylation | Lys24, Lys45 | Dimerization |
| Ubiquitination | Multiple | Degradation |
GABARAP undergoes a unique lipidation process similar to ubiquitination:
GABARAP (cytosolic)
↓ ATG7 (E1-like)
GABARAP ~Cys (thioester)
↓ ATG3 (E2-like)
GABARAP-PE (membrane-associated)
This lipidation is essential for GABARAP function in autophagy and is a key therapeutic target.
GABARAP interacts with numerous proteins:
| Partner | Interaction Type | Functional Outcome |
|---|---|---|
| GABA-A receptors | Direct binding | Receptor trafficking |
| LRRK2 | Direct binding | Autophagy regulation |
| p62/SQSTM1 | LIR-mediated | Selective autophagy |
| NBR1 | LIR-mediated | Aggregate clearance |
| ATG14 | Complex formation | Autophagosome initiation |
| ATG5 | Complex formation | Conjugation system |
| LC3 | Homology | Dimer formation |
| tubulins | Microtubule binding | Intracellular transport |
| syntaxin-17 | SNARE complex | Fusion |
GABARAP integrates with multiple signaling pathways:
GABARAP functions in multiple cellular processes[4]:
GABARAP was originally identified as a GABA-A receptor-associated protein:
GABARAP dysfunction contributes to AD pathogenesis:
GABARAP plays critical roles in PD pathophysiology:
GABARAP directly interacts with LRRK2, a key PD-linked protein:
| LRRK2 Mutation | Effect on GABARAP | Functional Outcome |
|---|---|---|
| G2019S | Enhanced binding | Dysregulated autophagy |
| R1441C/G/H | Reduced binding | Impaired mitophagy |
| N551K | Normal binding | Variable penetrance |
This interaction provides a mechanistic link between LRRK2 mutations and autophagy dysfunction in PD.
GABARAP interacts with multiple selective autophagy receptors:
Targeting GABARAP-mediated autophagy for neuroprotection:
| Approach | Mechanism | Development Stage |
|---|---|---|
| Autophagy enhancers | Activate GABARAP pathway | Preclinical |
| Small molecule modulators | Enhance GABARAP function | Discovery |
| Gene therapy | AAV-mediated GABARAP | Research |
| Combination therapy | Multi-target approaches | Preclinical |
GABARAP as a biomarker for neurodegenerative diseases:
Current therapeutic approaches targeting GABARAP-mediated autophagy:
| Drug | Mechanism | Trial Phase | Status |
|---|---|---|---|
| Rapamycin | mTORC1 inhibition | Phase 2 | Recruiting |
| Everolimus | mTORC1 inhibition | Phase 2 | Active |
| Temsirolimus | mTORC1 inhibition | Phase 1 | Completed |
| Drug | Mechanism | Trial Phase | Status |
|---|---|---|---|
| Metformin | AMPK activation | Phase 3 | Active |
| AICAR | Direct AMPK activation | Preclinical | Research |
| Compound | Mechanism | Development Stage |
|---|---|---|
| Trehalose | mTOR-independent autophagy | Preclinical |
| Spermidine | Autophagy induction | Phase 2 |
| Resveratrol | SIRT1/AMPK activation | Phase 2 |
| Variant | Effect | Disease Association |
|---|---|---|
| rs2373116 | Promoter polymorphism | PD risk |
| rs3745727 | Coding variant | AD risk |
| rs11549590 | 3'UTR variant | ALS risk |
GABARAP is highly conserved across species:
| Species | Homolog | Conservation |
|---|---|---|
| Human | GABARAP | Reference |
| Mouse | Gabarap | 98% identical |
| Zebrafish | gabarapa/b | 85% identical |
| Drosophila | dGABARAP | 72% identical |
| C. elegans | lgg-2 | 65% identical |
Key methods for studying GABARAP:
| Technique | Application |
|---|---|
| Western blot | Protein expression |
| Immunofluorescence | Subcellular localization |
| Co-IP | Protein interactions |
| Cryo-EM | Structural analysis |
| FRAP | Mobility studies |
| Mass spectrometry | PTM analysis |
Jo C, et al. Autophagy as an emerging therapeutic target for Alzheimer's disease. Nat Rev Neurosci. 2020. ↩︎
Lee JY, et al. GABARAP family proteins are essential for autophagy and neurological function. Mol Cell. 2019. ↩︎
Weiergraber OH, et al. Structural basis for the interaction of GABA receptor-associated protein (GABARAP) with microtubules. Cell Mol Life Sci. 2008. ↩︎
Nara A, et al. Golgi accumulation of autophagy proteins in neuronal cells. J Cell Sci. 2002. ↩︎
Su H, et al. The role of GABARAP in GABAergic signaling and synaptic plasticity. J Neurosci Res. 2020. ↩︎ ↩︎
Li L, et al. GABARAP-mediated mitophagy in neurodegenerative diseases. Cell Death Discov. 2022. ↩︎
Zhang Z, et al. Targeting GABARAP for therapeutic intervention in Alzheimer's disease. Pharmacol Res. 2021. ↩︎
Yang Y, et al. GABARAP family proteins in Parkinson's disease. J Mol Neurosci. 2018. ↩︎
Chen X, et al. GABARAP variants and risk of Parkinson's disease: A meta-analysis. Mov Disord. 2023. ↩︎
Schwarten M, et al. GABARAP directly binds LRRK2 to modulate autophagy. Autophagy. 2015. ↩︎